Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan
Authors:
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (3) , 815-820
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical ExperienceJournal of Stroke and Cerebrovascular Diseases, 2018
- Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial FibrillationJournal of the American Heart Association, 2018
- Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from TaiwanJournal of Stroke and Cerebrovascular Diseases, 2018
- Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial FibrillationStroke, 2017
- Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumabJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisNew England Journal of Medicine, 2017
- Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collectionInternational Journal of Stroke, 2017
- Management of Acute Stroke in Patients Taking Novel Oral AnticoagulantsInternational Journal of Stroke, 2014
- Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF TrialStroke, 2014
- Dabigatran Versus WarfarinStroke, 2013